OS Therapies Incorporated (OSTX)
XASE:OSTX
Want to see OSTX full AI Analyst Report?
OSTX Stock Chart & Stats
$1.44
$0.51(10.41%)
At close: 4:00 PM EST
$1.44
$0.51(10.41%)
Day’s Range― - ―
52-Week Range$1.15 - $2.57
Previous CloseN/A
Volume28.07K
Average Volume (3M)797.02K
Market Cap
$81.06M
Enterprise Value$502.44M
Total Cash (Recent Filing)$917.55M
Total Debt (Recent Filing)$1.34B
Price to Earnings (P/E)―
Beta-0.03
Next Earnings
Aug 13, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding44,538,105
10 Day Avg. Volume752,794
30 Day Avg. Volume797,017
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-6.72
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap6.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.39K
Enterprise Value/Ebitda-14.54
Forecast
1Y Price Target
$9.50Price Target Upside559.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.63
Revenue Forecast (FY)$4.75M
Bulls Say, Bears Say
Bulls Say
Biomarker EvidenceSubmission of a clinical and biomarker data package indicates a biomarker-driven response profile, which can enable targeted patient selection and strengthen the therapy's clinical differentiation.
Clinical OutcomesMid-stage and late-stage trial results showing superior event-free and overall survival versus historical controls suggest a meaningful clinical benefit that could support adoption and valuation upside.
Bears Say
Confirmatory Trial RequirementAccelerated approval efforts are expected to require a confirmatory study, which could delay full approval and increase resource and trial execution demands.
Liquidity RiskA net loss and very low cash balance, combined with recent financing that provides only limited runway, create material near-term funding risk that could force dilutive capital raises.
OS Therapies Incorporated News
OSTX FAQ
What was OS Therapies Incorporated’s price range in the past 12 months?
OS Therapies Incorporated lowest stock price was $1.15 and its highest was $2.57 in the past 12 months.
What is OS Therapies Incorporated’s market cap?
OS Therapies Incorporated’s market cap is $81.06M.
When is OS Therapies Incorporated’s upcoming earnings report date?
OS Therapies Incorporated’s upcoming earnings report date is Aug 13, 2026 which is in 82 days.
How were OS Therapies Incorporated’s earnings last quarter?
OS Therapies Incorporated released its earnings results on May 18, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.27.
Is OS Therapies Incorporated overvalued?
According to Wall Street analysts OS Therapies Incorporated’s price is currently Undervalued.
Does OS Therapies Incorporated pay dividends?
OS Therapies Incorporated does not currently pay dividends.
What is OS Therapies Incorporated’s EPS estimate?
OS Therapies Incorporated’s EPS estimate is -0.15.
How many shares outstanding does OS Therapies Incorporated have?
OS Therapies Incorporated has 44,538,105 shares outstanding.
What happened to OS Therapies Incorporated’s price movement after its last earnings report?
OS Therapies Incorporated reported an EPS of -$0.27 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.979%.
Which hedge fund is a major shareholder of OS Therapies Incorporated?
Currently, no hedge funds are holding shares in OSTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OS Therapies Incorporated Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.50 (559.72% Upside)
$9.50 (559.72% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.07%
12-Months-Change
Fundamentals
Return on Equity
9999.00%
Trailing 12-Months
Asset Growth
71.75%
Trailing 12-Months
Company Description
OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
OSTX Stock 12 Month Forecast
Average Price Target
$9.50
▲(559.72% Upside)
Technical Analysis
Ownership Overview
8.31% Insiders
1.39% Mutual Funds
1.69% Other Institutional Investors
87.57% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---